Your browser doesn't support javascript.
loading
Pancreatic glycoprotein 2 is a first line of defense for mucosal protection in intestinal inflammation.
Kurashima, Yosuke; Kigoshi, Takaaki; Murasaki, Sayuri; Arai, Fujimi; Shimada, Kaoru; Seki, Natsumi; Kim, Yun-Gi; Hase, Koji; Ohno, Hiroshi; Kawano, Kazuya; Ashida, Hiroshi; Suzuki, Toshihiko; Morimoto, Masako; Saito, Yukari; Sasou, Ai; Goda, Yuki; Yuki, Yoshikazu; Inagaki, Yutaka; Iijima, Hideki; Suda, Wataru; Hattori, Masahira; Kiyono, Hiroshi.
Afiliação
  • Kurashima Y; Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. yosukek@chiba-u.jp.
  • Kigoshi T; Department of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan. yosukek@chiba-u.jp.
  • Murasaki S; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. yosukek@chiba-u.jp.
  • Arai F; Division of Gastroenterology, Department of Medicine, CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines, University of California, San Diego, CA, USA. yosukek@chiba-u.jp.
  • Shimada K; Mucosal Immunology and Allergy Therapeutics, Institute for Global Prominent Research, Graduate School of Medicine, Chiba University, Chiba, Japan. yosukek@chiba-u.jp.
  • Seki N; Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Kim YG; Department of Pediatrics, Graduate School of Medicine, Tohoku University, Miyagi, Japan.
  • Hase K; Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Ohno H; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Kawano K; Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Ashida H; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Suzuki T; Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Morimoto M; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Saito Y; Division of Biochemistry, Graduate School of Pharmacological Science, Keio University, Tokyo, Japan.
  • Sasou A; Research Center for Drug Discovery, Faculty of Pharmacy, Keio University, Tokyo, Japan.
  • Goda Y; Research Center for Drug Discovery, Faculty of Pharmacy, Keio University, Tokyo, Japan.
  • Yuki Y; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Inagaki Y; Division of Biochemistry, Graduate School of Pharmacological Science, Keio University, Tokyo, Japan.
  • Iijima H; Laboratory for Intestinal Ecosystem, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
  • Suda W; Division of Immunobiology, Department of Medical Life Science, Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan.
  • Hattori M; Intestinal Microbiota Project, Kanagawa Institute of Industrial Science and Technology, Kanagawa, Japan.
  • Kiyono H; Laboratory for Intestinal Ecosystem, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Nat Commun ; 12(1): 1067, 2021 02 16.
Article em En | MEDLINE | ID: mdl-33594081
ABSTRACT
Increases in adhesive and invasive commensal bacteria, such as Escherichia coli, and subsequent disruption of the epithelial barrier is implicated in the pathogenesis of inflammatory bowel disease (IBD). However, the protective systems against such barrier disruption are not fully understood. Here, we show that secretion of luminal glycoprotein 2 (GP2) from pancreatic acinar cells is induced in a TNF-dependent manner in mice with chemically induced colitis. Fecal GP2 concentration is also increased in Crohn's diease patients. Furthermore, pancreas-specific GP2-deficient colitis mice have more severe intestinal inflammation and a larger mucosal E. coli population than do intact mice, indicating that digestive-tract GP2 binds commensal E. coli, preventing epithelial attachment and penetration. Thus, the pancreas-intestinal barrier axis and pancreatic GP2 are important as a first line of defense against adhesive and invasive commensal bacteria during intestinal inflammation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicoproteínas de Membrana / Inflamação / Mucosa Intestinal Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicoproteínas de Membrana / Inflamação / Mucosa Intestinal Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article